Effects of intrathecal injection of diatrizoate on dopamine receptors.
OBJECTIVE
The authors performed this study to determine whether adverse reactions similar to those that occur in patients receiving antipsychotic medication may occur after inadvertent intrathecal injections of some contrast material.


METHODS
Recombinant human dopamine-2 (D-2) receptors were incubated together with tritiated (hydrogen 3) spiperone, a D-2 receptor agonist commonly used in binding studies, and three types of contrast material (sodium/meglumine diatrizoate; meglumine iothalamate; and iohexol) in different concentrations to determine competitive binding potentials. Nonspecific binding was also assessed. Membranes were washed, filtered, and counted in a scintillation counter.


RESULTS
At several different concentrations, diatrizoate demonstrated a potential to displace the binding of spiperone to the D-2 receptors, whereas the other two contrast materials tested (iothalamate meglumine and iohexol) showed only weak binding potentials.


CONCLUSIONS
Diatrizoate, which has been incriminated in most adverse reactions resulting from the inadvertent intrathecal injection of a contrast material, may produce symptoms similar to those of the neuroleptic malignant syndrome by blocking neurotransmission through dopamine receptors. Although antipsychotic drugs produce this parkinsonism-like effect only after prolonged use, it is probable that diatrizoate produces the effect immediately by virtue of the high concentrations that may accumulate at the base of the brain after myelography. Also worthy of note is the fact that the two other contrast materials that have produced a number of reported adverse reactions share a molecular similarity to diatrizoate that is not found with other contrast materials.
Department of Radiology, University of California, San Diego, USA.
Elliott C
EC
Lasser
Geraldine E
GE
Lamkin
D000818:Animals; D003287:Contrast Media / Q000008:administration & dosage* / Q000633:toxicity; D006224:Cricetinae; D003412:Cricetulus; D003973:Diatrizoate / Q000008:administration & dosage* / Q000633:toxicity; D007278:Injections, Spinal; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology; D017448:Receptors, Dopamine D2 / Q000187:drug effects*
D003287:Contrast Media; D017448:Receptors, Dopamine D2; D003973:Diatrizoate